WO2007007159A3 - Anti-madcam antibodies to treat uterine disorders - Google Patents

Anti-madcam antibodies to treat uterine disorders Download PDF

Info

Publication number
WO2007007159A3
WO2007007159A3 PCT/IB2006/001886 IB2006001886W WO2007007159A3 WO 2007007159 A3 WO2007007159 A3 WO 2007007159A3 IB 2006001886 W IB2006001886 W IB 2006001886W WO 2007007159 A3 WO2007007159 A3 WO 2007007159A3
Authority
WO
WIPO (PCT)
Prior art keywords
madcam antibodies
uterine disorders
treat uterine
disorders
treatment
Prior art date
Application number
PCT/IB2006/001886
Other languages
French (fr)
Other versions
WO2007007159A2 (en
Inventor
Jeremy David Gale
Original Assignee
Pfizer Ltd
Jeremy David Gale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd, Jeremy David Gale filed Critical Pfizer Ltd
Publication of WO2007007159A2 publication Critical patent/WO2007007159A2/en
Publication of WO2007007159A3 publication Critical patent/WO2007007159A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The application relates to the use of an anti-MAdCAM antibody for the manufacture of a medicament for the treatment of uterine conditions such as endometriosis, dysmenorrhea, or pelvic inflammatory disease. Methods of treatment for uterine disorders using a therapeutically effective amount of an anti-MAdCAM antibody are also included.
PCT/IB2006/001886 2005-07-11 2006-07-03 Anti-madcam antibodies to treat uterine disorders WO2007007159A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69850605P 2005-07-11 2005-07-11
US60/698,506 2005-07-11

Publications (2)

Publication Number Publication Date
WO2007007159A2 WO2007007159A2 (en) 2007-01-18
WO2007007159A3 true WO2007007159A3 (en) 2007-07-12

Family

ID=37637546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001886 WO2007007159A2 (en) 2005-07-11 2006-07-03 Anti-madcam antibodies to treat uterine disorders

Country Status (1)

Country Link
WO (1) WO2007007159A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9328169B2 (en) 2004-01-09 2016-05-03 Pfizer Inc. Human antibodies that bind human MAdCAM

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151247A2 (en) 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY
CA2916283A1 (en) 2015-01-09 2016-07-09 Pfizer Inc. Dosage regimen for madcam antagonists
CR20200076A (en) 2017-07-14 2020-06-10 Pfizer Antibodies to madcam

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FERNEKORN UTA ET AL: "Functional involvement of P-selectin and MAdCAM-1 in the recruitment of alpha4beta7-integrin-expressing monocyte-like cells to the pregnant mouse uterus.", EUROPEAN JOURNAL OF IMMUNOLOGY DEC 2004, vol. 34, no. 12, December 2004 (2004-12-01), pages 3423 - 3433, XP000807663, ISSN: 0014-2980 *
HAWKINS R A ET AL: "Expression of mucosal homing receptor alpha4beta7 is associated with enhanced migration to the Chlamydia-infected murine genital mucosa in vivo.", INFECTION AND IMMUNITY OCT 2000, vol. 68, no. 10, October 2000 (2000-10-01), pages 5587 - 5594, XP008076700, ISSN: 0019-9567 *
OLSON KARA: "THE FDA APPROVES A NEW TREATMENT FOR MS", DIS NEWS THE UNIVERSITY OF MONTANA, vol. 9, no. 2, February 2005 (2005-02-01), XP002425585, Retrieved from the Internet <URL:http://www.health.umt.edu/DIS/pdf/February2005.pdf> *
WORMLEY F L JR ET AL: "Cell adhesion molecule and lymphocyte activation marker expression during experimental vaginal candidiasis.", INFECTION AND IMMUNITY AUG 2001, vol. 69, no. 8, August 2001 (2001-08-01), pages 5072 - 5079, XP008076657, ISSN: 0019-9567 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9328169B2 (en) 2004-01-09 2016-05-03 Pfizer Inc. Human antibodies that bind human MAdCAM

Also Published As

Publication number Publication date
WO2007007159A2 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
LUC00053I9 (en) ANTIBODIES AGAINST CD38 FOR THE TREATMENT OF MULTIPLE MYELOMA
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
WO2007033230A3 (en) Anti-cd3 antibody formulations
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2005103081A3 (en) Human monoclonal antibodies against cd20
WO2009061996A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
WO2006122257A3 (en) Nebulization of monoclonal antibodies for treating pulmonary diseases
WO2007024846A3 (en) Anit-il-23 antibiodies
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2007007173A3 (en) Human anti-madcam antibodies
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
PT1814915E (en) Neutralising antibodies having specificity for human il-17
MY147217A (en) Antibody molecules having specificity for human il-06
WO2007011907A3 (en) Alpha-synuclein antibodies and methods related thereto
WO2009021754A3 (en) Monospecific and multispecific antibodies and method of use
WO2006099698A3 (en) Novel anti-plgf antibody
WO2011004028A3 (en) Tlr3 binding agents
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2010066803A3 (en) Human antibodies against human tissue factor
WO2009052431A3 (en) Cd19 binding agents and uses thereof
WO2008019061A3 (en) Anti-il-6 monoclonal antibodies and uses thereof
WO2006021955A3 (en) Use of bat monoclonal antibody for immunotherapy
WO2009048538A3 (en) Use of anti-amyloid beta antibody in ocular diseases
WO2006105538A3 (en) Methods and compositions for treating il-21 related pathologies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06795083

Country of ref document: EP

Kind code of ref document: A2